Disease · MONDO_0022103

chronic prostatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic prostatitis. Diseases, record MONDO_0022103. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0022103

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic prostatitis; Open Targets
Open Targets ID: MONDO_0022103; Open Targets
NCI Thesaurus: C26930; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 14 drugs, from ClinicalTrials.gov; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DUTASTERIDE	CHEMBL1200969	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TAMSULOSIN	CHEMBL836	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALFUZOSIN	CHEMBL709	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INTERFERON GAMMA-1B	CHEMBL1201564	Protein	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PREGABALIN	CHEMBL1059	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
APREMILAST	CHEMBL514800	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTOSAN POLYSULFATE SODIUM	CHEMBL1201516	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SILODOSIN	CHEMBL24778	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets43

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	3	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1a adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
CACNA1A	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1E	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/777	Drugs and targets
CACNA1F	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1G	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8913	Drugs and targets

1 to 10 of 43

See all 43 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00371033	Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Phase 3	324	2025-09-22	Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00103402	Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Phase 3	272	2020-06-12	Prostatitis	ALFUZOSIN	Its record names the disease	ClinicalTrials.gov
NCT00402688	An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis	Phase 3	242	2009-07-16	Prostatitis	LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00740779	Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.	Phase 2	153	2012-02-24	Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome	SILODOSIN	Its record names the disease	ClinicalTrials.gov
NCT00701311	An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome	Phase 2	21	2014-05-16	Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT02711943	Non Interventional Study of Levofloxacin in Chronic Prostatitis		500		Chronic Prostatitis	LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00236990	An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland	Phase 2	283		Prostatitis	PENTOSAN POLYSULFATE SODIUM	Its record names the disease	ClinicalTrials.gov
NCT04756206	Role of Dutasteride in Treatment of Chronic Prostatitis	Phase 2/3	50		Dutasteride, Category IIIB Chronic Prostatitis	DUTASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT04446598	Management of Prostatodynia in Younger Patients With Non-ablative Erbium:YAG Intraurethral Laser	Not applicable	36		Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatodynia	TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT00913315	Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis	Not applicable	30		Prostatitis	TAMSULOSIN, TOLTERODINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
1-Pregabalin vs 2-Placebo: Moderately or Markedly Improve on Global Response Assessment (GRA)	68 of 218	20 of 106	324	NCT00371033	Trial comparisons
1-Pregabalin vs 2-Placebo: Decrease in the NIH-CPSI Total Score by at Least 6 Points	103 of 218	38 of 106	324	NCT00371033	Trial comparisons
1-Pregabalin vs 2-Placebo: deaths from any cause	0 of 218	0 of 106	324	NCT00371033	Trial comparisons
1-Pregabalin vs 2-Placebo: serious adverse events	0 of 218	0 of 106	324	NCT00371033	Trial comparisons
Alfuzosin vs Placebo: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks	68 of 138	66 of 134	272	NCT00103402	Trial comparisons
Alfuzosin vs Placebo: deaths from any cause	0 of 138	0 of 134	272	NCT00103402	Trial comparisons
Alfuzosin vs Placebo: serious adverse events	1 of 138	2 of 134	272	NCT00103402	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24726923	RESULT	1	PubMed
24686526	RESULT	1	PubMed
22341813	RESULT	1	PubMed
19092152	RESULT	1	PubMed
36570649	DERIVED	1	PubMed
21571345	DERIVED	1	PubMed
20876412	DERIVED	1	PubMed
20394471	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0022103

GET https://conductscience.org/api/diseases/v1/MONDO_0022103/targets?page=2

API reference For AI assistants